Cardiff University has been granted funding, to research which dietary supplement of Nicotinamide, a form of Vitamin B3, can be used to help reduce and possibly prevent, retinal damage in Glaucoma.
Fight for Sight has helped fund this important research which could help pave the way for new types of glaucoma treatments. Currently treatment is centred around reducing eye pressure and come at a great cost both financially and in time, to the patient and the health service.
As increased eye pressured is the main damaging driving force in glaucoma, the research will also test how effective Nicotinamide is in treating a wide range of eye pressure profiles.
There is currently a growing body of evidence which is shining a spotlight onto Nicotinamide and its protective role in preventing damage to retinal ganglion cells. (Retinal ganglion cell monitoring is now one of the latest ways to monitor and screen for glaucoma, it is also one of the earliest signs).